

Ramucirumab REACH-2


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



No QoL benefit

Serious and disabling adverse effects



Other adjustments



Ramucirumab REACH-2

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: As monotherapy for the treatment of adult patients with advanced or unresectable HCC who have serum AFP of ≥ 400 ng/ml and who have been previously treated with sorafenib

Experimental Arm: Ramucirumab

Control Arm: Placebo



